The global biologic therapeutics drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). The major factors contributing to the growth of the market include the rising prevalence of chronic disorders, including cancer, diabetes, and CVD. According to the World Health Organization (WHO), in 2020, the new cancer incidences reported was 19.3 million. Breast cancer was the most common cancer type in 2020 with almost 2.3 million cases, followed by lung cancer with 2.2 million cases, colon and rectum cancer with 1.9 million cases, prostate cancer with 1.4 million cases, and stomach cancer with 1.1 million cases.
Free Sample Copy @ https://www.omrglobal.com/request-sample/biologic-therapeutics-drugs-market
Additionally, the increase in the geriatric population is propelling the growth of the market. According to the World Population Prospects 2019, by United Nation Population Division, approximately 9.3% of the total population in 2019 was over 65 years of age. Moreover, the demand for innovative and advanced R&D approaches for the treatment of chronic diseases will boost the growth of the market. The rising geriatric population base is leading to an increased incidence of rheumatoid arthritis, which in turn, is accelerating the market growth.
A Full Report of Global Biologic Therapeutics Drugs Market is Available at:
https://www.omrglobal.com/industry-reports/biologic-therapeutics-drugs-market
Biological therapeutics is a field of research concerned with the development of medications and pharmaceutical products having biological origins. This field encompasses all pharmaceutical medication products made from semi-synthesized and biological sources. For rheumatoid arthritis, biological therapy targets the parts of the immune system that are triggering inflammation that causes joint and tissue damage. Some commonly used biological agents for the treatment of rheumatoid arthritis include SIMPONI ARIA (golimumab), REMICADE (infliximab), ACTEMRA (tocilizumab), ORENCIA (abatacept), RITUXAN (rituximab), and CIMZIA (certolizumab pegol). Some pipeline drugs have been witnessed, which is driving the market growth. For instance, in March 2021, Bicara Therapeutics launched a pipeline of dual-action biologics for cancer immunotherapy with a $40 million investment from Biocon Ltd. These pipeline drugs is offering an opportunity for market growth.
Global Biologic Therapeutics Drugs Market – Segmentation
By Product
Blood and Blood Products
Vaccines
Human Cells and Tissues
Cellular Therapies
Allergenic Extracts
Gene Therapies
Others
By Application
Rheumatoid Arthritis
Anemia
Cancer
Diabetes
Others
Global Biologic Therapeutics Drugs Market – Segmentation by Region
North America
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of the World
Company Profiles
Pfizer Inc.
AstraZeneca Plc
Novartis International AG
Merck & Co. Inc
GlaxoSmithKline Plc.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/biologic-therapeutics-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
(This release has been published on Global Market Post.
Global Market Post is not responsible for any content included in this release.)
